A phase 1 study of BHV-1530
Latest Information Update: 17 Mar 2025
At a glance
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2025 New trial record
- 03 Mar 2025 According to Biohaven Pharmaceuticals media release, the company plans to initiate this study in 1H 2025.